Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $1.8 million and $2.6 million for the three months ended June 30, 2022 and 2021, and $29.6 million and $6.3 million for the six months ended June 30, 2022 and 2021, respectively. The Company also recorded drug product revenue from Astellas of $1.1 million and $(2.0) million for the three months ended June 30, 2022 and 2021, and $8.7 million and $2.1 million for the six months ended June 30, 2022 and 2021, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, accounts receivable from Astellas were $26.1 million and $10.9 million, respectively. As of June 30, 2022 and December 31, 2021, total deferred revenue from Astellas was $54.9 million and $27.9 million, respectively. As of June 30, 2022, the amount due to Astellas was $43.3 million. As of December 31, 2021, amount due to Astellas was immaterial. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 3, Variable Interest Entity, for details. The net product revenue from Falikang was $19.7 million and $11.8 million for the three months ended June 30, 2022 and 2021, and $36.0 million and $22.2 million for the six months ended June 30, 2022 and 2021, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The investment income in Falikang was $0.6 million for each of the three months ended June 30, 2022 and 2021, and $0.9 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, the Company’s equity method investment in Falikang was $4.5 million and $3.8 million, respectively. See Note 3, Variable Interest Entity, for details. As of June 30, 2022, accounts receivable, net, from Falikang was of $0.7 million. As of December 31, 2021, accounts receivable, net, from Falikang was zero. The total deferred revenue from Falikang was zero as of June 30, 2022. The total deferred revenue from Falikang was $1.2 million as of December 31, 2021.

Related Party Transactions

6 Months Ended

Jun. 30, 2022

7. Related Party Transactions

Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $1.8 million and $2.6 million for the three months ended June 30, 2022 and 2021, and $29.6 million and $6.3 million for the six months ended June 30, 2022 and 2021, respectively. The Company also recorded drug product revenue from Astellas of $1.1 million and $(2.0) million for the three months ended June 30, 2022 and 2021, and $8.7 million and $2.1 million for the six months ended June 30, 2022 and 2021, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details.

The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2022 and 2021.

As of June 30, 2022 and December 31, 2021, accounts receivable from Astellas were $26.1 million and $10.9 million, respectively.

As of June 30, 2022 and December 31, 2021, total deferred revenue from Astellas was $54.9 million and $27.9 million, respectively.

As of June 30, 2022, the amount due to Astellas was $43.3 million. As of December 31, 2021, amount due to Astellas was immaterial.

Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 3, Variable Interest Entity, for details.

The net product revenue from Falikang was $19.7 million and $11.8 million for the three months ended June 30, 2022 and 2021, and $36.0 million and $22.2 million for the six months ended June 30, 2022 and 2021, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details.

The investment income in Falikang was $0.6 million for each of the three months ended June 30, 2022 and 2021, and $0.9 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, the Company’s equity method investment in Falikang was $4.5 million and $3.8 million, respectively. See Note 3, Variable Interest Entity, for details.

As of June 30, 2022, accounts receivable, net, from Falikang was of $0.7 million. As of December 31, 2021, accounts receivable, net, from Falikang was zero.

The total deferred revenue from Falikang was zero as of June 30, 2022. The total deferred revenue from Falikang was $1.2 million as of December 31, 2021.